Veru (VERU) Operating Expenses (2012 - 2024)
Veru (VERU) posted quarterly Operating Expenses of $11.1 million for Q3 2024, up 3.45% year-over-year from $10.7 million in Q4 2023, and down 10.49% quarter-over-quarter from $12.4 million in Q2 2024.
Veru (VERU) Operating Expenses (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Operating Expenses for 13 consecutive years, with $11.1 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Operating Expenses rose 3.45% year-over-year to $11.1 million; the TTM figure through Jun 2025 stood at $11.1 million (down 74.58% YoY), while the FY2024 annual figure was $44.0 million, down 58.91% from the prior year.
- Operating Expenses declined to $11.1 million in Q3 2024 per VERU's latest filing, from $12.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $45.4 million in Q3 2022 and bottomed at $6.7 million in Q3 2020.
- Historically, Operating Expenses has averaged $17.9 million across 5 years, with a median of $12.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 220.46% — and 2023, when it slumped 76.42%.
- Veru's Operating Expenses stood at $10.1 million in 2020, then soared by 67.05% to $16.8 million in 2021, then jumped by 127.07% to $38.2 million in 2022, then plunged by 73.92% to $10.0 million in 2023, then increased by 11.41% to $11.1 million in 2024.
- Business Quant data shows VERU's Operating Expenses at $11.1 million in Q3 2024, $12.4 million in Q2 2024, and $10.6 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 541.02 Mn |
| 10 | Veru | 61.31 Mn | 35.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 11.09 Mn |
| Jun 30, 2024 | 12.39 Mn |
| Mar 31, 2024 | 10.57 Mn |
| Dec 31, 2023 | 9.95 Mn |
| Sep 30, 2023 | 10.72 Mn |
| Jun 30, 2023 | 19.69 Mn |
| Mar 31, 2023 | 38.51 Mn |
| Dec 31, 2022 | 38.16 Mn |
| Sep 30, 2022 | 45.44 Mn |
| Jun 30, 2022 | 28.89 Mn |
| Mar 31, 2022 | 22.94 Mn |
| Dec 31, 2021 | 16.80 Mn |
| Sep 30, 2021 | 14.18 Mn |
| Jun 30, 2021 | 16.74 Mn |
| Mar 31, 2021 | 12.38 Mn |
| Dec 31, 2020 | 10.06 Mn |
| Sep 30, 2020 | 6.73 Mn |
| Jun 30, 2020 | 7.91 Mn |
| Mar 31, 2020 | 7.74 Mn |
| Dec 31, 2019 | 9.05 Mn |